- The FDA approves Medtronic's (NYSE:MDT) Valiant Navion thoracic stent graft system for the repair of all lesions of the descending thoracic aorta.
- The company says the product has a lower profile than the Valiant Captivia device enabling patients with small iliac arteries to be eligible for a TEVAR (thoracic endovascular aneurysm repair) procedure.
- Shares are down 2% premarket.